⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22294687 | 0.97 | TSHR (0.46) | — | |
| SCHEMBL7948788 | 0.97 | TSHR (0.46) | — | |
| SCHEMBL765938 | 0.97 | TSHR (0.46) | — | |
| SCHEMBL1687735 | 0.97 | TSHR (0.46) | — | |
| SCHEMBL4911816 | 0.97 | TSHR (0.46) | — | |
| SCHEMBL28391494 | 0.97 | TSHR (0.46) | — | |
| SCHEMBL10434646 | 0.97 | TSHR (0.46) | — | |
| SCHEMBL9803580 | 0.97 | TSHR (0.46) | — | |
| Hydrochloric Acid SCHEMBL27852088 | 0.95 | TSHR (0.44) | — | |
| SCHEMBL127102 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1469842-A4 | BICYCLIC CB2 CANNABINOID RECEPTOR LIGANDS | PHARMOS CORP (US) | 2006-04-26 | — | — | EP | claimed |
| JP-2005523259-A | — | — | 2005-08-04 | — | — | JP | claimed |
| US-20050020544-A1 | Bicyclic CB2 cannabinoid receptor ligands | PHARMOS CORPORATION | 2005-01-27 | — | — | US | claimed |
| EP-1469842-A2 | BICYCLIC CB2 CANNABINOID RECEPTOR LIGANDS | PHARMOS CORPORATION (US) | 2004-10-27 | — | — | EP | claimed |
| WO-2003063758-A2 | BICYCLIC CB2 CANNABINOID RECEPTOR LIGANDS | PHARMOS CORPORATION (US) | 2003-08-07 | — | — | WO | claimed |
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | INTELLIKINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180117060-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2018-05-03 | — | — | US | disclosed |
| US-9944638-B2 | Indoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND US (IE) | 2018-04-17 | — | — | US | disclosed |
| US-9944638-B2 | Indoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND US (IE) | 2018-04-17 | — | — | US | disclosed |
| US-9724354-B2 | Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2017-07-27 | — | — | US | disclosed |
| US-9669032-B2 | Enhanced treatment regimens using mTOR inhibitors | INTELLIKINE LLC (US) | 2017-06-06 | — | — | US | disclosed |
| CN-101115713-A | HIV protease inhibitors | MEDIVIR AB (SE) | 2008-01-30 | — | — | CN | disclosed |
| US-7071175-B1 | Pyridine mercapto carboxylic acids as carboxypeptidase U inhibitors | ASTRAZENECA AB (SE) | 2006-07-04 | — | — | US | disclosed |
| EP-1469842-A4 | BICYCLIC CB2 CANNABINOID RECEPTOR LIGANDS | PHARMOS CORP (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050020544-A1 | Bicyclic CB2 cannabinoid receptor ligands | PHARMOS CORPORATION | 2005-01-27 | — | — | US | disclosed |
| EP-1469842-A2 | BICYCLIC CB2 CANNABINOID RECEPTOR LIGANDS | PHARMOS CORPORATION (US) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003063758-A2 | BICYCLIC CB2 CANNABINOID RECEPTOR LIGANDS | PHARMOS CORPORATION (US) | 2003-08-07 | — | — | WO | disclosed |
| EP-1180098-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2002-02-20 | — | — | EP | disclosed |
| WO-2000066557-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2000-11-09 | — | — | WO | disclosed |